Paraneoplastic neurologic syndromes

Current Neurology and Neuroscience Reports

Volumn 6, Issue 3, 2006, Pages 193-199

  Vernino, Steven ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIPHYSIN; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARBONATE DEHYDRATASE III; CELL ANTIBODY; COLLAPSIN RESPONSE MEDIATOR PROTEIN; HU ANTIBODY;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; BLOOD ANALYSIS; BREAST CANCER; CANCER DIAGNOSIS; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC VALUE; ECHOGRAPHY; HUMAN; IMMUNE RESPONSE; INCIDENCE; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; PARANEOPLASTIC NEUROPATHY; PATHOLOGICAL ANATOMY; PERIPHERAL NERVOUS SYSTEM; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; PURKINJE CELL; REVIEW; T LYMPHOCYTE ACTIVATION;

ANTIBODIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; NERVOUS SYSTEM DISEASES; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; POSITRON-EMISSION TOMOGRAPHY; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 33646813666     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-006-0005-z     Document Type: Review

References (50)

1. Darnell RB, Posner JB: Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003, 349:1543-1554.
2. Graus F, Delattre JY, Antoine JC, et al.: Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004, 75:1135-1140.
3. Shams'ili S, Grefkens J, de Leeuw B, et al.: Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003, 126:1409-1418.
4. Lawn ND, Westmoreland BF, Kiely MJ, et al.: Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003, 78:1363-1368.
5. Voltz R, Gultekin SH, Rosenfeld MR, et al.: A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999, 340:1788-1795.
6. Vincent A, Buckley C, Schott JM, et al.: Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004, 127(Pt 3):701-712.
7. Thieben MJ, Lennon VA, Boeve BF, et al.: Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004, 62:1177-1182.
8. Buckley C, Oger J, Clover L, et al.: Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001, 50:73-78.
9. Ances BM, Vitaliani R, Taylor RA, et al.: Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005, 128(Pt 8):1764-1777.
10. Tani T, Piao Y, Mori S, et al.: Chorea resulting from paraneoplastic striatal encephalitis. J Neurol Neurosurg Psychiatry 2000, 69:512-515.
11. Croteau D, Owainati A, Dalmau J, Rogers LR: Response to cancer therapy in a patient with a paraneoplastic choreiform disorder. Neurology 2001, 57:719-722.
12. Vernino S, Tuite P, Adler CH, et al.: Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002, 51:625-630.
13. Cross SA, Salomao DR, Parisi JE, et al.: Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003, 54:38-50.
14. Balegno S, Ceroni M, Corato M, et al.: Antibodies to cerebellar nerve fibres in two patients with paraneoplastic cerebellar ataxia. Anticancer Res 2005, 25:3211-3214.
15. Batchelor TT, Platten M, Hochberg FH: Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol 1998, 40:131-136.
16. Eggers SD, Salomao DR, Dinapoli RP, Vernino S: Paraneoplastic and metastatic neurologic complications of Merkel cell carcinoma. Mayo Clin Proc 2001, 76:327-330.
17. Greenlee J, Steffens J, Clawson S, et al.: Anti-Hu antibodies in Merkel cell carcinoma. Ann Neurol 2002, 52:111-115.
18. Lopez MC, Pericay C, Agusti M, et al.: Merkel cell carcinoma associated with a paraneoplastic neurological syndrome. Histopathology 2004, 44:628-629.
19. Stein-Wexler R, Wootton-Gorges SL, Greco CM, Brunberg JA: Paraneoplastic limbic encephalitis in a teenage girl with an immature ovarian teratoma. Pediatr Radiol 2005, 35:694-697.
20. Taylor RB, Mason W. Kong K, Wennberg R: Reversible paraneoplastic encephalomyelitis associated with a benign ovarian teratoma. Can J Neurol Sci 1999, 26:317-320.
21. Vitaliani R, Mason W, Ances B, et al.: Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005, 58:594-604.
22. Pittock SJ, Kryzer TJ, Lennon VA: Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004, 56:715-719.
23. Honnorat J, Byk T, Kusters I, et al.: Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. Eur J Neurosci 1999, 11:4226-4232.
24. Yu Z, Kryzer TJ, Griesmann GE, et al.: CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001, 49:146-154.
25. Rosenfeld MR, Eichen JG, Wade DF, et al.: Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001, 50:339-348.
26. Dalmau J, Graus F, Villarejo A, et al.: Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004, 127(Pt 81:1831-1844.
27. Bataller L, Wade DF, Graus F, et al.: Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004, 62:778-782.
28. Chan KH, Vernino S, Lennon VA: ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001, 50:301-311.
29. Vernino S, Lennon VA: New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000, 47:297-305.
30. Graus F, Vincent A, Pozo-Rosich P, et al.: Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005, 165:166-171.
31. Bataller L, Sabater L, Saiz A, et al.: Carbonic anhydrase-related protein VIII: autoantigen in paraneoplastic cerebellar degeneration. Ann Neurol 2004, 56:575-579.
32. Storstein A, Knudsen A, Vedeler CA: Proteasome antibodies in paraneoplastic cerebellar degeneration. J Neuroimmunol 2005, 165:172-178.
33. Mutoh T, Tachi M, Yano S, et al.: Impairment of Trk-neurotrophin receptor by the serum of a patient with subacute sensory neuropathy. Arch Neurol 2005, 62:1612-1615.
34. Sillevis Smitt P, Kinoshita A, De Leeuw B, et al.: Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000, 342:21-27.
35. Bernal F, Shams'ili S, Rojas I, et al.: Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003, 60:230-234.
36. Coesmans M, Smitt PA, Linden DJ, et al.: Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 2003, 53:325-336.
37. Graus F, Lang B, Pozo-Rosich P, et al.: P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002, 59:764-766.
38. Candler PM, Hart PE, Barnett M, et al.: A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry 2004, 75:1411-1415.
39. Rees JH, Hain SF, Johnson MR, et al.: The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001, 124(Pt 11):2223-2231.
40. Linke R, Schroeder M, Helmberger T, Voltz R: Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004, 63:282-286.
41. Younes-Mhenni S, Janier MF, Cinotti L, et al.: FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004, 127:2331-2338.
42. Rousseau A, Benyahia B, Dalmau J, et al.: T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol 2005, 71:231-236.
43. Albert ML, Darnell JC, Bender A, et al.: Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998, 4:1321-1324.
44. Plonquet A, Gherardi RK, Creange A, et al.: Oligoclonal T-cells in blood and target tissues of patients with anti-Hu syndrome. J Neuroimmunol 2002, 122(1-2):100-105.
45. Albert ML, Austin LM, Darnell RB: Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000, 47:9-17.
46. Tanaka K, Tanaka M, Inuzuka T, et al.: Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody. J Neurol Sci 1999, 163:159-162.
47. Zhang L, Conejo-Garcia JR, Katsaros D, et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
48. Eerola AK, Soini Y, Paakko P: A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 2000, 6:1875-1881.
49. Vernino S, O'Neill BP, Marks RS, et al.: Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neurooncology 2004, 6:55-62.
50. Keime-Guibert F, Graus F, Fleury A, et al.: Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000, 68:479-482.